日本語English简体中文 繁體中文

4579 RaQualia Pharma Inc.ラクオリア創薬TSE Growth / Pharmaceuticals

0 posts

RaQualia Pharma Inc. (4579) at a glance

Code
4579
Company
RaQualia Pharma Inc.
Local name
ラクオリア創薬
Market
TSE Growth
Sector
Pharmaceuticals
Share price
¥740 +12.0 (+1.65%) Nov 20 close

Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.

RaQualia Pharma Inc. (4579) Stock Price History

RaQualia Pharma Inc. closed at ¥740 on Nov 20, 2026, +23.1% over 1 month, +2.8% over 1 year.

2026-11-13 2026年12月期 第3四半期決算短信〔日本基準〕(連結)¥743¥573Oct 20Nov 20
Price5-day MA25-day MANikkei 225Disclosures
1-Month High¥743Nov 17
1-Month Low¥573Nov 6
1-Week Change+14.6%vs Nov 13
1-Month Change+23.1%vs Oct 20

If you had invested ¥100,000 1 month ago, it would be worth ¥123,128 today (+23.1%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved −11.9%, while this stock moved +23.1%.

Board sentiment (last 30 days): 100% bullish / 0% bearish (1 votes)

Last 10 Trading Days

DateCloseChange% Change
Nov 20 (Fri)¥740+12+1.65%
Nov 19 (Thu)¥728+9+1.25%
Nov 18 (Wed)¥719−24−3.23%
Nov 17 (Tue)¥743+5+0.68%
Nov 16 (Mon)¥738+92+14.24%
Nov 13 (Fri)¥646−21−3.15%
Nov 12 (Thu)¥667−12−1.77%
Nov 11 (Wed)¥679+14+2.11%
Nov 10 (Tue)¥665+15+2.31%
Nov 9 (Mon)¥650+77+13.44%
2026-11-13 2026年12月期 第3四半期決算短信〔日本基準〕(連結)¥743¥542Aug 20Nov 20
Price5-day MA25-day MANikkei 225Disclosures
3-Month High¥743Nov 17
3-Month Low¥542Sep 11
1-Month Change+23.1%vs Oct 20
3-Month Change+26.3%vs Aug 20

If you had invested ¥100,000 3 months ago, it would be worth ¥126,280 today (+26.3%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved −14.8%, while this stock moved +26.3%.

Board sentiment (last 30 days): 100% bullish / 0% bearish (1 votes)

Last 10 Trading Days

DateCloseChange% Change
Nov 20 (Fri)¥740+12+1.65%
Nov 19 (Thu)¥728+9+1.25%
Nov 18 (Wed)¥719−24−3.23%
Nov 17 (Tue)¥743+5+0.68%
Nov 16 (Mon)¥738+92+14.24%
Nov 13 (Fri)¥646−21−3.15%
Nov 12 (Thu)¥667−12−1.77%
Nov 11 (Wed)¥679+14+2.11%
Nov 10 (Tue)¥665+15+2.31%
Nov 9 (Mon)¥650+77+13.44%
2026-11-13 2026年12月期 第3四半期決算短信〔日本基準〕(連結)¥743¥453May 20Nov 20
Price25-day MA75-day MANikkei 225Disclosures
6-Month High¥743Nov 17
6-Month Low¥453Jul 24
3-Month Change+26.3%vs Aug 20
6-Month Change+33.1%vs May 20

If you had invested ¥100,000 6 months ago, it would be worth ¥133,094 today (+33.1%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved −5.6%, while this stock moved +33.1%.

Monthly Closes

MonthMonth-End CloseMonthly %
Nov 2026¥740+16.0%
Oct 2026¥638+2.9%
Sep 2026¥620+9.5%
Aug 2026¥566+17.4%
Jul 2026¥482+1.9%
Jun 2026¥473−5.6%
May 2026¥501−35.9%
2026-11-13 2026年12月期 第3四半期決算短信〔日本基準〕(連結)¥1,429¥453Nov 20Nov 20
Price25-day MA75-day MANikkei 225Disclosures
52-Week High¥1,429Dec 8
52-Week Low¥453Jul 24
Year to Date−26.7%vs Dec 30
From 52-Week High−48.2%Dec 8

If you had invested ¥100,000 1 year ago, it would be worth ¥102,778 today (+2.8%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved +13.3%, while this stock moved +2.8%.

Monthly Closes

MonthMonth-End CloseMonthly %
Nov 2026¥740+16.0%
Oct 2026¥638+2.9%
Sep 2026¥620+9.5%
Aug 2026¥566+17.4%
Jul 2026¥482+1.9%
Jun 2026¥473−5.6%
May 2026¥501−35.9%
Apr 2026¥781+0.4%
Mar 2026¥778−22.7%
Feb 2026¥1,007−0.8%
Jan 2026¥1,015+0.5%
Dec 2025¥1,010+11.7%
Nov 2025¥904―
¥1,212¥332Nov 20, 2023Nov 20, 2026
Price13-week MA26-week MANikkei 225
3-Year High¥1,212Dec 12, 2025
3-Year Low¥332Apr 7, 2025
Annualized Return−3.0%
Max Drawdown−62.6%

If you had invested ¥100,000 3 years ago, it would be worth ¥91,245 today (−8.8%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved +67.8%, while this stock moved −8.8%.

Yearly Closes

YearYear-End CloseYearly %
2026 (YTD)¥740−26.7%
2025¥1,010―
¥1,387¥332Nov 22, 2021Nov 20, 2026
Price13-week MA26-week MANikkei 225
5-Year High¥1,387Dec 5, 2022
5-Year Low¥332Apr 7, 2025
Annualized Return−4.3%
Max Drawdown−76.1%

If you had invested ¥100,000 5 years ago, it would be worth ¥80,087 today (−19.9%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved +96.3%, while this stock moved −19.9%.

Yearly Closes

YearYear-End CloseYearly %
2026 (YTD)¥740−26.7%
2025¥1,010―
¥2,756¥241Aug 1, 2011Nov 20, 2026
Price1-year MA2-year MANikkei 225
All-Time High¥2,756Jan 2018
All-Time Low¥241Oct 2012
Total Change−7.5%vs Aug 2011
Annualized Return−0.5%

If you had invested ¥100,000 in Aug 2011, it would be worth ¥92,500 today (−7.5%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved +548.7%, while this stock moved −7.5%.

Yearly Closes

YearYear-End CloseYearly %
2026 (YTD)¥740−26.7%
2025¥1,010+163.0%
2024¥384−44.2%
2023¥688−44.2%
2022¥1,232+4.9%
2021¥1,174+17.4%
2020¥1,000−25.4%
2019¥1,341+24.5%
2018¥1,077−54.2%
2017¥2,350+493.4%
2016¥396+17.9%
2015¥336−23.6%
2014¥440−35.4%
2013¥681+95.7%
2012¥348−42.0%
2011¥600―

Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Aug 2011). Please check the latest prices before trading.

RaQualia Pharma Inc. (4579) financial indicators

PBR
2.49
ROE
-0.87%
Dividend yield
0.00%

See all financial indicators for RaQualia Pharma Inc. (market cap, DOE, equity ratio, EV, EBITDA, ROIC and more)

PER, ROE and dividend yield are based on company forecasts, calculated from earnings reports and the closing price after each trading day.

Key features of RaQualia Pharma Inc. (4579)

Business overview

Together with two consolidated subsidiaries, the company is an R&D-driven drug discovery venture aiming to create new drugs for disease areas with high medical needs using advanced science and technology, and it has a single segment. Its basic business is earning revenue by licensing out the intellectual property rights of development compounds it has created to pharmaceutical companies and others. In January 2026 it absorbed subsidiary 「テムリック」. As success rates for new drug development fall and costs rise, pharmaceutical companies are actively bringing in high-quality development compounds from outside, and in the United States about 60% of new drugs are said to originate from biotech ventures. Beyond its own R&D, the company is deepening cooperation with academia, startups and others to build a next-generation drug discovery value chain.

Summarized from the annual securities report (fiscal year ended December 2025) filed on EDINET.

Position within Pharmaceuticals (79 companies)

PBR2.49xAbove the sector median of 1.86x (No. 51 from the lowest)
ROE-0.87%No. 35 in the sector (highest first); median 4.17%
Market cap¥19.3 bnNo. 39 in the sector (largest first)

Ranks among stocks in the same Tokyo Stock Exchange sector (33 sectors). PER and PBR of zero or below (losses, negative equity) are excluded and ranked from the lowest.

Price milestones

52-week high¥1,4292025/12/8
52-week low¥4537/29
Current position29.4%Where the low is 0% and the high is 100% (close on 11/20: ¥740)
Year to date-26.7%No. 50 of 77 in the sector (best first)
1 year+2.8%

Based on closing prices (adjusted for stock splits, excluding dividends).

Kabutaro's ranking history

Top 50 gainers2 timesLatest: 11/16 (No. 25)

Gainers and losers have been recorded since 9/2026.

Calculated as of 2026/11/20 17:30 JST. Updated every business day in the evening.

Recent disclosures (TDnet, in Japanese)

Filings from the past 12 months (4).

Posts

This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.

No posts yet. Be the first to write something.

Write on the RaQualia Pharma Inc. board

You will need this to delete your post. Please keep it safe.
By posting you agree to the board rules (Japanese). You are responsible for what you write.

More Japanese stocks in English

Japanese Stock Message Board: stocks available in English

Other boards in English